Regeneron Pharmaceuticals is expanding its manufacturing capabilities in Ireland with the addition of 400 new jobs.
The additional staff will bring total headcount to over 1,400 at its Industrial Operations and Product Supply (IOPS) campus in the Limerick area.
The new jobs will support the production of the company’s existing medicines. Regeneron is maximising manufacturing capacity at its New York facility for REGN-COV2, its investigational two-antibody combination being developed for the potential treatment and prevention of COVID-19.
Since 2014, Regeneron has invested over $1 billion to build the largest bulk biologics production facility in the country, with over 1,000 employees, more than 300 contingent workers and close to 500 construction personnel currently working on site.
Recruitment is underway to hire full-time, high-end specialist jobs in commercial manufacturing, process sciences, quality assurance/control, supply chain and various support functions for scientists, chemists and technicians.